Advances in neoantigens and tumor immunotherapy / 肿瘤

ABSTRACT

In recent years, with the development of tumor immunology research, the immunotherapy represented by immune checkpoint inhibitors has achieved gratifying clinical efficacy in various solid tumors. At the same time, the immunotherapy of cancer still faces many challenges. For example, the efficacy of immunotherapy is difficult to predict. How to choose the benefit population? How to improve the efficacy and reduce side effects? All of these are urgent problems to be solved. Neoantigens are a kind of peptides encoded by the mutant somatic genes. They can be recognized by the immune system, and can trigger the anti-tumor immune reaction of the body. Therefore, the development of neoantigens has been one of important ways to solve these problems above. The characteristics and detection methods of neoantigens, as well as the progress in the current applications of immunological checkpoint inhibitor therapy, adoptive cell therapy and tumor vaccine are reviewed in this paper.